Literature DB >> 10723586

Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation.

C Hirt1, G Dölken.   

Abstract

The aim of this study was to evaluate whether a quantitative analysis of circulating t(14;18)-positive cells is of prognostic significance in patients with follicular lymphoma (FL) after myelo-ablative therapy supported by ABMT. We tested DNA from primary lymphoma tissue as well as PBMC before and after ABMT from 15 patients for the presence of the t(14;18) translocation. Nine patients showed a t(14;18) translocation, six patients were t(14;18)-negative. Circulating t(14;18)-positive cells of seven patients were quantitatively determined by limiting dilution assays combined with a two-step PCR and by real-time quantitative PCR. The results of both methods correlate very well. The number of circulating t(14;18)-positive cells decreased significantly in all patients after myeloablative therapy and ABMT, t(14;18)-negative blood samples were found in five of seven patients. In all patients circulating t(14;18)-positive cells reappeared within 2 years after ABMT showing two different patterns. During continuous CR the numbers of circulating t(14;18)-positive cells were found to be stable within one order of magnitude. In contrast, in one patient the relapse was accompanied by a logarithmic increase of t(14;18)-positive cells. In a second patient the enlargement of lymph nodes developing over a period of 12 months was accompanied by very slowly increasing numbers of t(14;18)-positive cells. In all cases where diagnostic lymph node tissue was available, the same t(14;18) translocation was found at first diagnosis and after ABMT as shown by nucleotide sequence analysis. We conclude that the quantitative detection of circulating t(14;18)-positive cells during follow-up of patients with FL after ABMT reflects the clinical course of the disease. Relapses are associated with increasing numbers of circulating t(14;18)-positive cells and continuous complete remissions with stable cell counts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10723586     DOI: 10.1038/sj.bmt.1702147

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Quantitative assessment of disease involvement by follicular lymphoma using real-time polymerase chain reaction measurement of t(14;18)-carrying cells.

Authors:  Woo-In Lee; Fernando Cabanillas; Ming-Sheng Lee
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

2.  Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.

Authors:  Nancy Pennell; Anthony Woods; Marciano Reis; Rena Buckstein; David Spaner; Kevin Imrie; Karen Hewitt; Angela Boudreau; Arun Seth; Neil L Berinstein
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

3.  t(14;18) Translocations and risk of follicular lymphoma.

Authors:  Charles S Rabkin; Carsten Hirt; Siegfried Janz; Gottfried Dölken
Journal:  J Natl Cancer Inst Monogr       Date:  2008

4.  Quantitative PCR detection of t(14;18) bcl-2/JH fusion sequences in follicular lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples.

Authors:  Alex Bowman; Dan Jones; L Jeffrey Medeiros; Rajyalakshmi Luthra
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.